Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

ICI-182780 associated with longer remission duration than megestrol in resistant breast cancer

Dec. 22, 1997

Peptidomimetic inhibitors of protein farnesyltransferase from Merck & Co.

Dec. 22, 1997

Squalamine enters phase I for the treatment of cancer

Dec. 22, 1997

FDA Advisory Committee does not recommend approval for DepoCyt

Dec. 19, 1997

Farnesyltransferase inhibitors lacking a thiol moiety from Merck & Co.

Dec. 19, 1997

More on protein farnesyltransferase inhibitors from Merck & Co.

Dec. 18, 1997

Chemoprotective properties of lisofylline reported

Dec. 18, 1997

Indomethacin: antitumor activity and effects on telomerase

Dec. 17, 1997

Clinical evaluation of adenoviral-p53 gene therapy for prostate cancer begins

Dec. 17, 1997

Burzynski's antineoplastons in phase II testing for multiple oncology indications

Dec. 17, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...